Takeda Pharmaceutical Co Ltd (TAK)
13.62
+0.06
(+0.41%)
USD |
NYSE |
Nov 15, 16:00
13.62
0.00 (0.00%)
After-Hours: 18:20
Takeda Pharmaceutical PE Ratio: 22.54 for Nov. 15, 2024
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| November 14, 2024 | 22.45 |
| November 13, 2024 | 22.44 |
| November 12, 2024 | 22.40 |
| November 11, 2024 | 22.58 |
| November 08, 2024 | 22.80 |
| November 07, 2024 | 22.93 |
| November 06, 2024 | 22.82 |
| November 05, 2024 | 23.53 |
| November 04, 2024 | 23.25 |
| November 01, 2024 | 23.10 |
| October 31, 2024 | 23.06 |
| October 30, 2024 | 22.98 |
| October 29, 2024 | 22.92 |
| October 28, 2024 | 22.50 |
| October 25, 2024 | 22.45 |
| October 24, 2024 | 22.83 |
| October 23, 2024 | 22.93 |
| October 22, 2024 | 23.38 |
| October 21, 2024 | 23.41 |
| October 18, 2024 | 23.71 |
| October 17, 2024 | 23.59 |
| October 16, 2024 | 23.30 |
| October 15, 2024 | 23.25 |
| October 14, 2024 | 23.73 |
| October 11, 2024 | 23.66 |
| Date | Value |
|---|---|
| October 10, 2024 | 23.68 |
| October 09, 2024 | 23.63 |
| October 08, 2024 | 23.66 |
| October 07, 2024 | 23.71 |
| October 04, 2024 | 23.87 |
| October 03, 2024 | 23.56 |
| October 02, 2024 | 23.69 |
| October 01, 2024 | 23.63 |
| September 30, 2024 | 23.53 |
| September 27, 2024 | 47.55 |
| September 26, 2024 | 47.91 |
| September 25, 2024 | 47.68 |
| September 24, 2024 | 48.40 |
| September 23, 2024 | 48.70 |
| September 20, 2024 | 48.40 |
| September 19, 2024 | 48.83 |
| September 18, 2024 | 48.47 |
| September 17, 2024 | 48.57 |
| September 16, 2024 | 48.40 |
| September 13, 2024 | 48.08 |
| September 12, 2024 | 48.47 |
| September 11, 2024 | 48.47 |
| September 10, 2024 | 48.70 |
| September 09, 2024 | 48.67 |
| September 06, 2024 | 48.44 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
9.384
Minimum
Dec 01 2021
482.81
Maximum
Feb 06 2020
56.96
Average
27.51
Median
PE Ratio Benchmarks
| HUTCHMED (China) Ltd | -- |
| Astellas Pharma Inc | 183.47 |
| Nxera Pharma Co Ltd | -- |
| PeptiDream Inc | 15.66 |
| Healios KK | -- |
PE Ratio Related Metrics
| PS Ratio | 1.439 |
| PEG Ratio | 0.6240 |
| Price to Book Value | 0.8914 |
| Price to Free Cash Flow | 12.61 |
| Price | 13.62 |
| Earnings Yield | 4.44% |
| Market Cap | 43.20B |
| PEGY Ratio | 0.5548 |
| Operating PE Ratio | 13.84 |
| Normalized PE Ratio | 22.54 |